Fig. 1: DOT cells target CRC in vitro.
a, Schematic representation and tumor cell death quantification by annexin V in 3-h killing assays of DOT cells against different MSI and MSS CRC cell lines. Colors depict individual DOT donors (pool of 16 assays). Data were analyzed by a two-tailed paired t-test for normal distributions or Wilcoxon matched-pairs ranked test for nonnormal distributions. b, Schematic representation and DOT cell killing of CD45-depleted primary CRC tumor specimens, measured by caspase 3/7 staining. Lines connect specimens from the same participant (n = 6 participants, pool of five assays). Data were analyzed by a two-tailed paired t-test. c, Experimental layout and percentage of apoptotic tumor cells (measured by caspase 3/7 green staining) in the presence or absence of allogeneic DOT cells and/or TILs from the same participants (n = 7 participants). Samples from participants with MMR-p/MSS and MMR-d/MSI CRC are represented as circles and squares, respectively. d, Expression of CD69 and 4-1BB by DOT cells in the presence or absence of PDOs and/or TILs. Lines connect data points from the same participants (n = 7 participants). In c and d, data are a pool of four different assays and were analyzed by a repeated-measures one-way ANOVA with Holm–Šidák’s multiple-comparisons test.
